This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pregnancy and Breast Feeding  • Alert me on articles by topic

Arch Pediatr Adolesc Med. 2003;157:601.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a controlled cohort study, Costei et al¹ reported higher rates of neonatal complications (mainly respiratory distress) and prematurity with third-trimester maternal use of paroxetine and raised the question whether other selective serotonin reuptake inhibitors cause neonatal complications similar to those reported in the study. We wish to interpret their findings within the context of other data. In a larger study, Chambers et al² reported higher rates of prematurity, admission to special-care nurseries, and poor neonatal adaptation (including respiratory distress) associated with third-trimester exposure to fluoxetine. Another study has linked third-trimester exposure to fluoxetine to higher rates of perinatal complications but 4 other studies have not.³

These studies were prospective investigations in which the estimates of perinatal complications associated with late exposure to antidepressants were subjected to a number of confounding factors, including maternal smoking, concurrent psychotherapeutic medications, and severity of depressive symptoms.^1-2 Because of these issues, improved methods of . . . [Full Text of this Article]